Ikonomidis Ignatios, Lekakis John, Vamvakou Georgia, Andreotti Felicita, Nihoyannopoulos Petros
Imperial College School of Medicine, National Heart and Lung Institute, Cardiology Department, Hammersmith Hospital, London, United Kingdom.
Am Heart J. 2005 May;149(5):832-9. doi: 10.1016/j.ahj.2004.08.030.
Smoking is associated with endothelial dysfunction. Cytokines released by injured endothelium promote vascular interactions with leukocytes and platelets. We investigated whether (a) cigarette smoking is linked to increased cytokine production, which may mediate platelet activation and thrombin generation in chronic coronary artery disease (CAD), and (b) aspirin treatment inhibits smoking-related changes on cytokines, platelets, and thrombin.
Plasma macrophage-colony-stimulating factor (M-CSF) and C-reactive protein (CRP) were measured in 100 patients with chronic CAD, 60 of whom were chronic smokers. Prothrombin fragments 1+2 and urinary 11-dehydro-thromboxane B2 (TXB2) were additionally measured in 60 of 100 patients (30 of whom were smokers) and in 24 healthy controls. Smokers (n = 20) matched for age, myocardial ischemia, and other risk factors with 20 nonsmokers entered a double-blind crossover trial of aspirin (300 mg/d for 3 weeks) versus placebo. Blood and urine measurements were repeated after each treatment. Compared with nonsmokers, smokers had 3-fold median M-CSF (1499 vs 476 pg/mL), 2-fold CRP (1.5 vs 0.8 mg/L), and higher 11-dehydro-TXB 2 (3.6 vs 2.1 ng/mg creatinine, P < .01 for all comparisons). After aspirin treatment, M-CSF, CRP, 11-dehydro-TXB 2 , and prothrombin fragments 1+2 remained higher in smokers compared with nonsmokers despite a significant reduction of these markers by aspirin (P < .05). M-CSF remained related to 11-dehydro-TXB 2 excretion during both treatment phases (P < .01) suggesting that cytokine-mediated thromboxane A 2 production was not altered by aspirin.
Smoking is associated with increased M-CSF, CRP, and platelet activity. Although aspirin treatment reduces the proinflammatory and procoagulant markers in smokers, it does not abolish the proinflammatory effects of smoking in patients with chronic CAD.
吸烟与内皮功能障碍有关。受损内皮释放的细胞因子促进血管与白细胞和血小板的相互作用。我们研究了:(a)吸烟是否与细胞因子产生增加有关,而细胞因子产生增加可能介导慢性冠状动脉疾病(CAD)中的血小板活化和凝血酶生成;(b)阿司匹林治疗是否抑制吸烟相关的细胞因子、血小板和凝血酶变化。
对100例慢性CAD患者测定血浆巨噬细胞集落刺激因子(M-CSF)和C反应蛋白(CRP),其中60例为慢性吸烟者。在100例患者中的60例(其中30例为吸烟者)以及24例健康对照者中额外测定凝血酶原片段1+2和尿11-脱氢血栓烷B2(TXB2)。20名年龄、心肌缺血及其他危险因素相匹配的吸烟者与20名不吸烟者进入阿司匹林(300mg/d,共3周)与安慰剂的双盲交叉试验。每次治疗后重复进行血液和尿液检测。与不吸烟者相比,吸烟者的M-CSF中位数高3倍(1499对476pg/mL),CRP高2倍(1.5对0.8mg/L),11-脱氢TXB2也更高(3.6对2.1ng/mg肌酐,所有比较P<0.01)。阿司匹林治疗后,尽管这些指标因阿司匹林而显著降低(P<0.05),但吸烟者的M-CSF、CRP、11-脱氢TXB2和凝血酶原片段1+2仍高于不吸烟者。在两个治疗阶段,M-CSF均与11-脱氢TXB2排泄相关(P<0.01),提示细胞因子介导的血栓烷A2生成未被阿司匹林改变。
吸烟与M-CSF、CRP升高及血小板活性增加有关。虽然阿司匹林治疗可降低吸烟者的促炎和促凝指标,但并不能消除吸烟对慢性CAD患者的促炎作用。